199 results on '"Greenberg, Steven M."'
Search Results
2. Cerebral Amyloid Angiopathy
- Author
-
Greenberg, Steven M. and van Veluw, Susanne J.
- Published
- 2024
- Full Text
- View/download PDF
3. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
- Author
-
Shirzadi, Zahra, Schultz, Stephanie A., Yau, Wai-Ying W., Joseph-Mathurin, Nelly, Fitzpatrick, Colleen D., Levin, Raina, Kantarci, Kejal, Preboske, Gregory M., Jack, Clifford R., Farlow, Martin R., Hassenstab, Jason, Jucker, Mathias, Morris, John C., Xiong, Chengjie, Karch, Celeste M., Levey, Allan I., Gordon, Brian A., Schofield, Peter R., Salloway, Stephen P., Perrin, Richard J., McDade, Eric, Levin, Johannes, Cruchaga, Carlos, Allegri, Ricardo F., Fox, Nick C., Goate, Alison, Day, Gregory S., Koeppe, Robert, Chui, Helena C., Berman, Sarah, Mori, Hiroshi, Sanchez-Valle, Raquel, Lee, Jae-Hong, Rosa-Neto, Pedro, Ruthirakuhan, Myuri, Wu, Che-Yuan, Swardfager, Walter, Benzinger, Tammie L. S., Sohrabi, Hamid R., Martins, Ralph N., Bateman, Randall J., Johnson, Keith A., Sperling, Reisa A., Greenberg, Steven M., Schultz, Aaron P., and Chhatwal, Jasmeer P.
- Abstract
IMPORTANCE: Increased white matter hyperintensity (WMH) volume is a common magnetic resonance imaging (MRI) finding in both autosomal dominant Alzheimer disease (ADAD) and late-onset Alzheimer disease (LOAD), but it remains unclear whether increased WMH along the AD continuum is reflective of AD-intrinsic processes or secondary to elevated systemic vascular risk factors. OBJECTIVE: To estimate the associations of neurodegeneration and parenchymal and vessel amyloidosis with WMH accumulation and investigate whether systemic vascular risk is associated with WMH beyond these AD-intrinsic processes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 3 longitudinal cohort studies conducted in tertiary and community-based medical centers—the Dominantly Inherited Alzheimer Network (DIAN; February 2010 to March 2020), the Alzheimer’s Disease Neuroimaging Initiative (ADNI; July 2007 to September 2021), and the Harvard Aging Brain Study (HABS; September 2010 to December 2019). MAIN OUTCOME AND MEASURES: The main outcomes were the independent associations of neurodegeneration (decreases in gray matter volume), parenchymal amyloidosis (assessed by amyloid positron emission tomography), and vessel amyloidosis (evidenced by cerebral microbleeds [CMBs]) with cross-sectional and longitudinal WMH. RESULTS: Data from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). Longitudinal increases in WMH volume were greater in individuals with CMBs compared with those without (DIAN: t = 3.2 [P = .001]; ADNI: t = 2.7 [P = .008]), associated with longitudinal decreases in gray matter volume (DIAN: t = −3.1 [P = .002]; ADNI: t = −5.6 [P < .001]; HABS: t = −2.2 [P = .03]), greater in older individuals (DIAN: t = 6.8 [P < .001]; ADNI: t = 9.1 [P < .001]; HABS: t = 5.4 [P < .001]), and not associated with systemic vascular risk (DIAN: t = 0.7 [P = .40]; ADNI: t = 0.6 [P = .50]; HABS: t = 1.8 [P = .06]) in individuals with ADAD and LOAD after accounting for age, gray matter volume, CMB presence, and amyloid burden. In older adults without CMBs at baseline, greater WMH volume was associated with CMB development during longitudinal follow-up (Cox proportional hazards regression model hazard ratio, 2.63; 95% CI, 1.72-4.03; P < .001). CONCLUSIONS AND RELEVANCE: The findings suggest that increased WMH volume in AD is associated with neurodegeneration and parenchymal and vessel amyloidosis but not with elevated systemic vascular risk. Additionally, increased WMH volume may represent an early sign of vessel amyloidosis preceding the emergence of CMBs.
- Published
- 2023
- Full Text
- View/download PDF
4. Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage
- Author
-
Al-Shahi Salman, Rustam and Greenberg, Steven M.
- Abstract
This focused update about antiplatelet agents to reduce the high risk of major adverse cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral hemorrhage (ICH) complements earlier updates about blood pressure-lowering, lipid-lowering, and oral anticoagulation or left atrial appendage occlusion for atrial fibrillation after ICH. When used for secondary prevention in people without ICH, antiplatelet agents reduce the risk of major adverse cardiovascular event (rate ratio, 0.81 [95% CI, 0.75–0.87]) and might increase the risk of ICH (rate ratio, 1.67 [95% CI, 0.97–2.90]). Before 2019, guidance for clinical decisions about antiplatelet agent use after ICH has focused on estimating patients’ predicted absolute risks and severities of ischemic and hemorrhagic major adverse cardiovascular event and applying the known effects of these drugs in people without ICH to estimate whether individual ICH survivors in clinical practice might be helped or harmed by antiplatelet agents. In 2019, the main results of the RESTART (Restart or Stop Antithrombotics Randomized Trial) randomized controlled trial including 537 survivors of ICH associated with antithrombotic drug use showed, counterintuitively, that antiplatelet agents might not increase the risk of recurrent ICH compared to antiplatelet agent avoidance over 2 years of follow-up (12/268 [4%] versus 23/268 [9%]; adjusted hazard ratio, 0.51 [95% CI, 0.25–1.03]; P=0.060). Guidelines in the United States, Canada, China, and the United Kingdom and Ireland have classified the level of evidence as B and indicated that antiplatelet agents may be considered/reasonable after ICH associated with antithrombotic agent use. Three subsequent clinical trials have recruited another 174 participants with ICH, but they will not be sufficient to determine the effects of antiplatelet therapy on all major adverse cardiovascular events reliably when pooled with RESTART. Therefore, ASPIRING (Antiplatelet Secondary Prevention International Randomized Study After Intracerebral Hemorrhage) aims to recruit 4148 ICH survivors to determine the effects of antiplatelet agents after ICH definitively overall and in subgroups.
- Published
- 2023
- Full Text
- View/download PDF
5. Apathy in Patients With Cerebral Amyloid Angiopathy
- Author
-
Chokesuwattanaskul, Anthipa, Zanon Zotin, Maria Clara, Schoemaker, Dorothée, Sveikata, Lukas, Gurol, M. Edip, Greenberg, Steven M., and Viswanathan, Anand
- Published
- 2023
- Full Text
- View/download PDF
6. Sex Differences in Onset and Progression of Cerebral Amyloid Angiopathy
- Author
-
Koemans, Emma A., Castello, Juan Pablo, Rasing, Ingeborg, Abramson, Jessica R., Voigt, Sabine, Perosa, Valentina, van Harten, Thijs W., van Zwet, Erik W., Terwindt, Gisela M., Gurol, M. Edip, Rosand, Jonathan, Greenberg, Steven M., van Walderveen, Marianne A.A., Biffi, Alessandro, Viswanathan, Anand, and Wermer, Marieke J.H.
- Published
- 2023
- Full Text
- View/download PDF
7. Using Noncontrast Computed Tomography to Improve Prediction of Intracerebral Hemorrhage Expansion
- Author
-
Morotti, Andrea, Boulouis, Gregoire, Nawabi, Jawed, Li, Qi, Charidimou, Andreas, Pasi, Marco, Schlunk, Frieder, Shoamanesh, Ashkan, Katsanos, Aristeidis H., Mazzacane, Federico, Busto, Giorgio, Arba, Francesco, Brancaleoni, Laura, Giacomozzi, Sebastiano, Simonetti, Luigi, Warren, Andrew D., Laudisi, Michele, Cavallini, Anna, Gurol, Edip M., Viswanathan, Anand, Zini, Andrea, Casetta, Ilaria, Fainardi, Enrico, Greenberg, Steven M., Padovani, Alessandro, Rosand, Jonathan, and Goldstein, Joshua N.
- Published
- 2023
- Full Text
- View/download PDF
8. Association of Depression Onset and Treatment With Blood Pressure Control After Intracerebral Hemorrhage
- Author
-
Keins, Sophia, Abramson, Jessica R., Mallick, Akashleena, Pablo Castello, Juan, Rodriguez-Torres, Axana, Popescu, Dominique, Hoffman, Danielle, Kourkoulis, Christina, Gurol, M. Edip, Greenberg, Steven M., Anderson, Christopher D., Viswanathan, Anand, Rosand, Jonathan, and Biffi, Alessandro
- Published
- 2023
- Full Text
- View/download PDF
9. Blood Pressure Control Targets and Risk of Cardiovascular and Cerebrovascular Events After Intracerebral Hemorrhage
- Author
-
Teo, Kay-Cheong, Keins, Sophia, Abramson, Jessica R., Leung, William C.Y., Leung, Ian Y.H., Wong, Yuen-Kwun, Yeung, Charming, Kourkoulis, Christina, Warren, Andrew D., Chan, Koon-Ho, Cheung, Raymond T.F., Ho, Shu-Leong, Gurol, M. Edip, Viswanathan, Anand, Greenberg, Steven M., Anderson, Christopher D., Lau, Kui-Kai, Rosand, Jonathan, and Biffi, Alessandro
- Published
- 2023
- Full Text
- View/download PDF
10. Forkhead box O3 longevity genotype may attenuate the impact of hypertension on risk of intracerebral haemorrhage
- Author
-
Nakagawa, Kazuma, Chen, Randi, Greenberg, Steven M., Ross, G. Webster, Willcox, Bradley J., Donlon, Timothy A., Allsopp, Richard C., Willcox, D. Craig, Morris, Brian J., and Masaki, Kamal H.
- Published
- 2022
- Full Text
- View/download PDF
11. Cerebral Amyloid Angiopathy and Nontraumatic Subdural Hemorrhage
- Author
-
Bax, Francesco and Greenberg, Steven M.
- Published
- 2024
- Full Text
- View/download PDF
12. Seed to Bleed: Iatrogenic Cerebral Amyloid Angiopathy
- Author
-
Greenberg, Steven M. and Charidimou, Andreas
- Published
- 2023
- Full Text
- View/download PDF
13. Lobar intracerebral hemorrhage and risk of subsequent uncontrolled blood pressure
- Author
-
Myserlis, Evangelos Pavlos, Mayerhofer, Ernst, Abramson, Jessica R, Teo, Kay-Cheong, Montgomery, Bailey E., Sugita, Lansing, Warren, Andrew D, Goldstein, Joshua N, Gurol, Mahmut Edip, Viswanathan, Anand, Greenberg, Steven M, Biffi, Alessandro, Anderson, Christopher D, and Rosand, Jonathan
- Abstract
Background: Uncontrolled blood pressure (BP) in intracerebral hemorrhage (ICH) survivors is common and associated with adverse clinical outcomes. We investigated whether characteristics of the ICH itself were associated with uncontrolled BP at follow-up.Methods: Subjects were consecutive patients aged ⩾18 years with primary ICH enrolled in the prospective longitudinal ICH study at Massachusetts General Hospital between 1994 and 2015. We assessed the prevalence of uncontrolled BP (mean BP ⩾140/90 mmHg) 6 months after index event. We used multivariable logistic regression models to assess the effect of hematoma location, volume, and event year on uncontrolled BP.Results: Among 1492 survivors, ICH was lobar in 624 (42%), deep in 749 (50%), cerebellar in 119 (8%). Lobar ICH location was associated with increased risk for uncontrolled BP after 6 months (OR 1.35; 95% CI [1.08–1.69]). On average, lobar ICH survivors were treated with fewer antihypertensive drugs compared to the rest of the cohort: 2.1 ± 1.1 vs 2.5 ± 1.2 (p< 0.001) at baseline and 1.8 ± 1.2 vs. 2.4 ± 1.2 (p< 0.001) after 6 months follow-up. After adjustment for the number of antihypertensive drugs prescribed, the association of lobar ICH location with risk of uncontrolled BP was eliminated.Conclusions: ICH survivors with lobar hemorrhage were more likely to have uncontrolled BP after 6 months follow-up. This appears to be a result of being prescribed fewer antihypertensive medications. Future treatment strategies should focus on aggressive BP control after ICH independent of hemorrhage location.
- Published
- 2022
- Full Text
- View/download PDF
14. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation
- Author
-
Eckman, Mark H., Rosand, Jonathan, Greenberg, Steven M., and Gage, Brian F.
- Subjects
Atrial fibrillation -- Drug therapy ,Hemorrhage -- Risk factors ,Pharmacogenetics -- Research ,Warfarin -- Dosage and administration ,Warfarin -- Complications and side effects ,Health - Abstract
Background: Variants in genes involved in warfarin metabolism and sensitivity affect individual warfarin requirements and the risk for bleeding. Testing for these variant alleles might allow more personalized dosing of warfarin during the induction phase. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey), suggesting that clinicians consider genetic testing before initiating therapy. Objective: To examine the cost-effectiveness of genotype-guided dosing versus standard induction of warfarin therapy for patients with nonvalvular atrial fibrillation. Design: Markov state transition decision model. Data Sources: MEDLINE searches and bibliographies from relevant articles of literature published in English. Target Population: Outpatients or inpatients requiring initiation of warfarin therapy. The base case was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications to warfarin therapy. Time Horizon: Lifetime. Perspective: Societal. Intervention: Genotype-guided dosing consisting of genotyping for CYP2C9*2, CYP2C9*3, and/or VKORC1 versus standard warfarin induction. Outcome Measures: Effectiveness was measured in quality-adjusted life-years (QALYs), and costs were in 2007 U.S. dollars. Results: In the base case, genotype-guided dosing resulted in better outcomes, but at a relatively high cost. Overall, the marginal cost-effectiveness of testing exceeded $170 000 per QALY. On the basis of current data and cost of testing (about $400), there is only a 10% chance that genotype-guided dosing is likely to be cost-effective (that is, Limitation: Few published studies describe the effect of genotype-guided dosing on major bleeding events, and although these studies show a trend toward decreased bleeding, the results are not statistically significant. Conclusion: Warfarin-related genotyping is unlikely to be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effective in patients at high risk for hemorrhage who are starting warfarin therapy. Funding: The National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Foundation for Informed Medical Decision Making; National Institutes of Neurological Disorders and Stroke; Deane Institute for Integrative Study of Atrial Fibrillation and Stroke; and American Heart Association.
- Published
- 2009
15. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association
- Author
-
Greenberg, Steven M., Ziai, Wendy C., Cordonnier, Charlotte, Dowlatshahi, Dar, Francis, Brandon, Goldstein, Joshua N., Hemphill, J. Claude, Johnson, Ronda, Keigher, Kiffon M., Mack, William J., Mocco, J., Newton, Eileena J., Ruff, Ilana M., Sansing, Lauren H., Schulman, Sam, Selim, Magdy H., Sheth, Kevin N., Sprigg, Nikola, and Sunnerhagen, Katharina S.
- Published
- 2022
- Full Text
- View/download PDF
16. Longitudinal Progression of Magnetic Resonance Imaging Markers and Cognition in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
- Author
-
van Dijk, Suzanne E., van der Grond, Jeroen, Lak, Jessie, van den Berg-Huysmans, Annette, Labadie, Gerda, Terwindt, Gisela M., Wermer, Marieke J.H., Gurol, M. Edip, van Buchem, Mark A., Greenberg, Steven M., and van Rooden, Sanneke
- Published
- 2022
- Full Text
- View/download PDF
17. Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association
- Author
-
Ganesh, Aravind, Fraser, Justin F., Gordon Perue, Gillian L., Amin-Hanjani, Sepideh, Leslie-Mazwi, Thabele M., Greenberg, Steven M., Couillard, Philippe, Asdaghi, Negar, and Goyal, Mayank
- Abstract
Patients with premorbid disability or dementia have generally been excluded from randomized controlled trials of reperfusion therapies such as thrombolysis and endovascular therapy for acute ischemic stroke. Consequently, stroke physicians face treatment dilemmas in caring for such patients. In this scientific statement, we review the literature on acute ischemic stroke in patients with premorbid disability or dementia and propose principles to guide clinicians, clinician-scientists, and policymakers on the use of acute stroke therapies in these populations. Recent clinical-epidemiological studies have demonstrated challenges in our concept and measurement of premorbid disability or dementia while highlighting the significant proportion of the general stroke population that falls under this umbrella, risking exclusion from therapies. Such studies have also helped clarify the adverse long-term clinical and health economic consequences with each increment of additional poststroke disability in these patients, underscoring the importance of finding strategies to mitigate such additional disability. Several observational studies, both case series and registry-based studies, have helped demonstrate the comparable safety of endovascular therapy in patients with premorbid disability or dementia and in those without, complementing similar data on thrombolysis. These data also suggest that such patients have a substantial potential to retain their prestroke level of disability when treated, despite their generally worse prognosis overall, although this remains to be validated in higher-quality registries and clinical trials. By pairing pragmatic and transparent decision-making in clinical practice with an active pursuit of high-quality research, we can work toward a more inclusive paradigm of patient-centered care for this often-neglected patient population.
- Published
- 2022
- Full Text
- View/download PDF
18. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation
- Author
-
Fang, Margaret C., Chang, Yuchiao, Hylek, Elaine M., Rosand, Jonathan, Greenberg, Steven M., Go, Alan S., and Singer, Daniel E.
- Subjects
Warfarin -- Adverse and side effects ,Warfarin -- Research ,Atrial fibrillation -- Care and treatment ,Atrial fibrillation -- Research ,Health - Abstract
Background: The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity. Objective: To examine the relationship of age, anticoagulation intensity, and risk for intracranial hemorrhage. Design: Case-control study. Setting: Academic medical center. Patients: 170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation. Measurements: The authors performed multivariable conditional logistic regression to determine the odds of intracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for comorbid conditions and aspirin use. Results: Case-patients were older than controls (median age, 78 years vs. 75 years; P < 0.001) and had higher median INRs (2.7 vs. 2.3; P < 0.001). The risk for intracranial hemorrhage increased at 85 years of age or older (adjusted odds ratio, 2.5 [95% CI, 1.3 to 4.7]; referent age, 70 to 74 years) and at an INR range of 3.5 to 3.9 (adjusted odds ratio, 4.6 [CI, 2.3 to 9.4]; referent INR, 2.0 to 3.0). The risk for intracranial hemorrhage at INRs less than 2.0 did not differ statistically from the risk at INRs of 2.0 to 3.0 (adjusted odds ratio, 1.3 [CI, 0.8 to 2.2]). Limitations: Although duration of anticoagulation has been associated with hemorrhage in other studies, the current study could not control for this potential confounder. Conclusions: The risk for intracranial hemorrhage increases at age 85 years. International normalized ratios less than 2.0 were not associated with lower risk for intracranial hemorrhage compared with INRs between 2.0 and 3.0. Therefore, anticoagulation management should focus on maintaining INRs in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than targeting INRs less than 2.0. Similarly, INRs of 3.5 or greater should be avoided.
- Published
- 2004
19. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage
- Author
-
Rosand, Jonathan, Eckman, Mark H., Knudsen, Katherine A., Singer, Daniel E., and Greenberg, Steven M.
- Subjects
Warfarin -- Dosage and administration ,Warfarin -- Adverse and side effects ,Anticoagulants (Medicine) -- Dosage and administration ,Anticoagulants (Medicine) -- Adverse and side effects ,Health - Published
- 2004
20. Biological and Social Determinants of Hypertension Severity Before vs After Intracerebral Hemorrhage
- Author
-
Abramson, Jessica R., Castello, Juan Pablo, Keins, Sophia, Kourkoulis, Christina, Rodriguez-Torres, Axana, Myserlis, Evangelos Pavlos, Alabsi, Haitham, Warren, Andrew D., Henry, Jonathan Q.A., Gurol, M. Edip, Viswanathan, Anand, Greenberg, Steven M., Towfighi, Amytis, Skolarus, Lesli, Anderson, Christopher D., Rosand, Jonathan, and Biffi, Alessandro
- Published
- 2022
- Full Text
- View/download PDF
21. Maximizing Brain Health After Hemorrhagic Stroke: Bugher Foundation Centers of Excellence
- Author
-
Sheth, Kevin N., Anderson, Christopher D., Biffi, Alessandro, Dlamini, Nomazulu, Falcone, Guido J., Fox, Christine K., Fullerton, Heather J., Greenberg, Steven M., Hemphill, J. Claude, Kim, Anthony, Kim, Helen, Ko, Nerissa U., Roland, Jarod L., Sansing, Lauren H., van Veluw, Susanne J., and Rosand, Jonathan
- Published
- 2022
- Full Text
- View/download PDF
22. Cerebral Small Vessel Disease and Depression Among Intracerebral Hemorrhage Survivors
- Author
-
Castello, Juan Pablo, Pasi, Marco, Kubiszewski, Patryk, Abramson, Jessica R., Charidimou, Andreas, Kourkoulis, Christina, DiPucchio, Zora, Schwab, Kristin, Anderson, Christopher D., Gurol, M. Edip, Greenberg, Steven M., Rosand, Jonathan, Viswanathan, Anand, and Biffi, Alessandro
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2022
- Full Text
- View/download PDF
23. Cerebellar atrophy and its implications on gait in cerebral amyloid angiopathy
- Author
-
Horn, Mitchell J, Gokcal, Elif, Becker, Alex J, Das, Alvin S, Warren, Andrew D, Schwab, Kristin, Goldstein, Joshua. N, Biffi, Alessandro, Rosand, Jonathan, Polimeni, Jonathan R, Viswanathan, Anand, Greenberg, Steven M, and Gurol, M Edip
- Abstract
ObjectiveRecent data suggest that cerebral amyloid angiopathy (CAA) causes haemorrhagic lesions in cerebellar cortex as well as subcortical cerebral atrophy. However, the potential effect of CAA on cerebellar tissue loss and its clinical implications have not been investigated.MethodsOur study included 70 non-demented patients with probable CAA, 70 age-matched healthy controls (HCs) and 70 age-matched patients with Alzheimer’s disease (AD). The cerebellum was segmented into percent of cerebellar subcortical volume (pCbll-ScV) and percent of cerebellar cortical volume (pCbll-CV) represented as percent (p) of estimated total intracranial volume. We compared pCbll-ScV and pCbll-CV between patients with CAA, HCs and those with AD. Gait velocity (metres/second) was used to investigate gait function in patients with CAA.ResultsPatients with CAA had significantly lower pCbll-ScV compared with both HC (1.49±0.1 vs 1.73±0.2, p<0.001) and AD (1.49±0.1 vs 1.66[Formula]0.24, p<0.001) and lower pCbll-CV compared with HCs (6.03±0.5 vs 6.23±0.6, p=0.028). Diagnosis of CAA was independently associated with lower pCbll-ScV compared with HCs (p<0.001) and patients with AD (p<0.001) in separate linear regression models adjusted for age, sex and presence of hypertension. Lower pCbll-ScV was independently associated with worse gait velocity (β=0.736, 95% CI 0.28 to 1.19, p=0.002) in a stepwise linear regression analysis including pCbll-CV along with other relevant variables.InterpretationPatients with CAA show more subcortical cerebellar atrophy than HC or patients with AD and more cortical cerebellar atrophy than HCs. Reduced pCbll-ScV correlated with lower gait velocity in regression models including other relevant variables. Overall, this study suggests that CAA causes cerebellar injury, which might contribute to gait disturbance.
- Published
- 2022
- Full Text
- View/download PDF
24. Computed Tomography Angiography Spot Sign, Hematoma Expansion, and Functional Outcome in Spontaneous Cerebellar Intracerebral Hemorrhage
- Author
-
Singh, Sanjula D., Pasi, Marco, Schreuder, Floris H.B.M., Morotti, Andrea, Senff, Jasper R., Warren, Andrew D., McKaig, Brenna N., Schwab, Kristin, Gurol, M. Edip, Rosand, Jonathan, Greenberg, Steven M., Viswanathan, Anand, Klijn, Catharina J.M., Rinkel, Gabriel J.E., Goldstein, Joshua N., and Brouwers, H. Bart
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2021
- Full Text
- View/download PDF
25. Cerebral Amyloid Angiopathy–Related Transient Focal Neurologic Episodes
- Author
-
Smith, Eric E., Charidimou, Andreas, Ayata, Cenk, Werring, David J., and Greenberg, Steven M.
- Abstract
Transient focal neurologic episodes (TFNEs) are brief disturbances in motor, somatosensory, visual, or language functions that can occur in patients with cerebral amyloid angiopathy (CAA) and may be difficult to distinguish from TIAs or other transient neurologic syndromes. They herald a high rate of future lobar intracerebral hemorrhage, making it imperative to differentiate them from TIAs to avoid potentially dangerous use of antithrombotic drugs. Cortical spreading depression or depolarization triggered by acute or chronic superficial brain bleeding, a contributor to brain injury in other neurologic diseases, may be the underlying mechanism. This review discusses diagnosis, pathophysiology, and management of CAA-related TFNEs.
- Published
- 2021
- Full Text
- View/download PDF
26. Rare Missense Functional Variants at COL4A1and COL4A2in Sporadic Intracerebral Hemorrhage
- Author
-
Chung, Jaeyoon, Hamilton, Graham, Kim, Minsup, Marini, Sandro, Montgomery, Bailey, Henry, Jonathan, Cho, Art E., Brown, Devin L., Worrall, Bradford B., Meschia, James F., Silliman, Scott L., Selim, Magdy, Tirschwell, David L., Kidwell, Chelsea S., Kissela, Brett, Greenberg, Steven M., Viswanathan, Anand, Goldstein, Joshua N., Langefeld, Carl D., Rannikmae, Kristiina, Sudlow, Catherine L.M., Samarasekera, Neshika, Rodrigues, Mark, Al-Shahi Salman, Rustam, Prendergast, James G.D., Harris, Sarah E., Deary, Ian, Woo, Daniel, Rosand, Jonathan, Van Agtmael, Tom, and Anderson, Christopher D.
- Published
- 2021
- Full Text
- View/download PDF
27. Hematoma Expansion in Intracerebral Hemorrhage With Unclear Onset
- Author
-
Morotti, Andrea, Boulouis, Gregoire, Charidimou, Andreas, Li, Qi, Poli, Loris, Costa, Paolo, De Giuli, Valeria, Leuci, Eleonora, Mazzacane, Federico, Busto, Giorgio, Arba, Francesco, Brancaleoni, Laura, Giacomozzi, Sebastiano, Simonetti, Luigi, Laudisi, Michele, Micieli, Giuseppe, Cavallini, Anna, Candeloro, Elisa, Gamba, Massimo, Magoni, Mauro, Warren, Andrew D., Anderson, Christopher D., Gurol, M. Edip, Biffi, Alessandro, Viswanathan, Anand, Casetta, Ilaria, Fainardi, Enrico, Zini, Andrea, Pezzini, Alessandro, Padovani, Alessandro, Greenberg, Steven M., Rosand, Jonathan, and Goldstein, Joshua N.
- Published
- 2021
- Full Text
- View/download PDF
28. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
- Author
-
Girard, Romuald, Li, Yan, Stadnik, Agnieszka, Shenkar, Robert, Hobson, Nicholas, Romanos, Sharbel, Srinath, Abhinav, Moore, Thomas, Lightle, Rhonda, Shkoukani, Abdallah, Akers, Amy, Carroll, Timothy, Christoforidis, Gregory A, Koenig, James I, Lee, Cornelia, Piedad, Kristina, Greenberg, Steven M, Kim, Helen, Flemming, Kelly D, Ji, Yuan, and Awad, Issam A
- Abstract
Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
29. Vascular Contributions to Brain Health
- Author
-
Greenberg, Steven M.
- Abstract
As life expectancy grows, brain health is increasingly seen as central to what we mean by successful aging—and vascular brain health as central to overall brain health. Cerebrovascular pathologies are highly prevalent independent contributors to age-related cognitive impairment and at least partly modifiable with available treatments. The current Focused Update addresses vascular brain health from multiple angles, ranging from pathophysiologic mechanisms and neuroimaging features to epidemiologic risk factors, social determinants, and candidate treatments. Here we highlight some of the shared themes that cut across these distinct perspectives: (1) the lifetime course of vascular brain injury pathogenesis and progression; (2) the scientific and ethical imperative to extend vascular brain health research in non-White and non-affluent populations; (3) the need for improved tools to study the cerebral small vessels themselves; (4) the potential role for brain recovery mechanisms in determining vascular brain health and resilience; and (5) the cross-pathway mechanisms by which vascular and neurodegenerative processes may interact. The diverse perspectives featured in this Focused Update offer a sense of the multidisciplinary approaches and collaborations that will be required to launch our populations towards improved brain health and successful aging.
- Published
- 2022
- Full Text
- View/download PDF
30. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity
- Author
-
Kubiszewski, Patryk, Sugita, Lansing, Kourkoulis, Christina, DiPucchio, Zora, Schwab, Kristin, Anderson, Christopher D., Gurol, M. Edip, Greenberg, Steven M., Viswanathan, Anand, Rosand, Jonathan, and Biffi, Alessandro
- Abstract
IMPORTANCE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat poststroke depression but are associated with increased incidence of first-ever intracerebral hemorrhage (ICH) in the general population. The decision to treat ICH survivors with SSRIs must therefore balance potential risks of ICH recurrence with presumed benefits on depressive symptoms. OBJECTIVE: To determine whether SSRI use among survivors of primary ICH was associated with ICH recurrence and decreased severity of depressive symptoms. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal ICH cohort study at a tertiary care center enrolling from January 2006 to December 2017, with follow-up for a median of 53.2 months (interquartile range, 42.3-61.2 months). The study included 1279 consenting individuals (1049 White, 89 Black, 77 Hispanic, and 64 other race/ethnicity) of 1335 eligible patients presenting with primary ICH and who were discharged alive from initial hospitalization for stroke. MAIN OUTCOMES AND MEASURES: We conducted univariable and multivariable analyses for ICH recurrence risk and depression severity, including subset analyses for patients with 1 or more of the following characteristics associated with high ICH recurrence risk: (1) lobar ICH; (2) presence of the apolipoprotein ε2/ε4 gene variants; (3) prior history of ICH/TIA/ischemic stroke; and (4) Black or Hispanic race/ethnicity. RESULTS: Mean age of study participants was 71.3 years, with 602 women (47%); of the 1279 participants, 1049 were White, 89 were Black, 77 were Hispanic, and 64 were other race/ethnicity. SSRI exposure was associated with both ICH recurrence (subhazard ratio [SHR], 1.31; 95% CI, 1.08-1.59) and resolution of post-ICH depression (SHR, 1.53; 95% CI, 1.12 2.09). Among those individuals at high risk for recurrent ICH, SSRIs were associated with further elevation in risk for ICH recurrence (SHR, 1.79; 95% CI, 1.22-2.64) compared with all other survivors of ICH (SHR, 1.20; 95% CI, 1.01-1.42; P = .008 for comparison of effect sizes). The association of SSRI with reduced depressive symptoms did not differ between high those at high risk for recurrent ICH and all other ICH survivors. CONCLUSIONS AND RELEVANCE: Selective serotonin reuptake inhibitor exposure after ICH is associated with both improvement in depressive symptoms and increased risk of recurrent hemorrhagic stroke. Clinical history, neuroimaging data, and genetic biomarkers may help to identify survivors of ICH more likely to safely tolerate SSRI use.
- Published
- 2021
- Full Text
- View/download PDF
31. Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation
- Author
-
Regenhardt, Robert W., Thon, Jesse M., Das, Alvin S., Thon, Olga R., Charidimou, Andreas, Viswanathan, Anand, Gurol, M. Edip, Chwalisz, Bart K., Frosch, Matthew P., Cho, Tracey A., and Greenberg, Steven M.
- Abstract
IMPORTANCE: Cerebral amyloid angiopathy–related inflammation (CAA-ri), a distinct subtype of cerebral amyloid angiopathy, is characterized by an autoimmune reaction to cerebrovascular β-amyloid deposits. Outcomes and response to immunosuppressive therapy for CAA-ri are poorly understood. OBJECTIVE: To identify clinical, neuroimaging, laboratory, pathologic, or treatment-related associations with outcomes after an episode of CAA-ri. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of prospectively identified individuals who presented from July 3, 1998, to November 27, 2017, with a median follow-up of 2.7 years (interquartile range, 1.0-5.5 years). The study included 48 consecutive patients with CAA-ri meeting diagnostic criteria who had at least 1 disease episode and subsequent outcome data. No patients refused or were excluded. EXPOSURES: Prespecified candidate variables were immunosuppressive therapies, cerebrospinal fluid pleocytosis, magnetic resonance imaging findings of recent infarcts or contrast enhancement, and histopathologic evidence of vessel wall inflammation. MAIN OUTCOMES AND MEASURES: Clinical improvement and worsening were defined by persistent changes in signs or symptoms, radiographic improvement by decreased subcortical foci of T2 hyperintensity or T1 enhancement, and radiographic worsening by increased subcortical T2 hyperintensity, T1 enhancement, or infarcts. Disease recurrence was defined as new-onset clinical symptoms associated with new imaging findings. RESULTS: The 48 individuals in the study included 29 women and had a mean (SD) age of 68.9 (9.9) years. Results of presenting magnetic resonance imaging revealed that 10 of 29 patients with CAA-ri (34%) had T1 contrast enhancement, 30 of 32 (94%) had subcortical T2 hyperintensity (22 of 30 [73%] asymmetric), 7 of 32 (22%) had acute or subacute punctate infarcts, and 27 of 31 (87%) had microbleeds. Immunosuppressive treatments after first episodes included corticosteroids (33 [69%]), cyclophosphamide (6 [13%]), and mycophenolate (2 [4%]); 14 patients (29%) received no treatment. Clinical improvement and radiographic improvement were each more likely in individuals treated with an immunosuppressive agent than with no treatment (clinical improvement: 32 of 34 [94%] vs 7 of 14 [50%]; odds ratio, 16.0; 95% CI, 2.72-94.1; radiographic improvement: 24 of 28 [86%] vs 4 of 14 [29%]; odds ratio, 15.0; 95% CI, 3.12-72.1). Recurrence was less likely if CAA-ri was treated with any immunosuppressant agent than not (9 of 34 [26%] vs 10 of 14 [71%]; hazard ratio, 0.19; 95% CI, 0.07-0.48). When controlling for treatment, no variables were associated with outcomes aside from an association between APOE ɛ4 and radiographic improvement (odds ratio, 4.49; 95% CI, 1.11-18.2). CONCLUSIONS AND RELEVANCE: These results from a relatively large series of patients with CAA-ri support the effectiveness of immunosuppressive treatment and suggest that early treatment may both improve the initial disease course and reduce the likelihood of recurrence. These results raise the possibility that early blunting of CAA-ri and the autoimmune response may have long-term benefits for the subsequent disease course.
- Published
- 2020
- Full Text
- View/download PDF
32. Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage
- Author
-
Biffi, Alessandro, Urday, Sebastian, Kubiszewski, Patryk, Gilkerson, Lee, Sekar, Padmini, Rodriguez-Torres, Axana, Bettin, Margaret, Charidimou, Andreas, Pasi, Marco, Kourkoulis, Christina, Schwab, Kristin, DiPucchio, Zora, Behymer, Tyler, Osborne, Jennifer, Morgan, Misty, Moomaw, Charles J., James, Michael L., Greenberg, Steven M., Viswanathan, Anand, Gurol, M. Edip, Worrall, Bradford B., Testai, Fernando D., McCauley, Jacob L., Falcone, Guido J., Langefeld, Carl D., Anderson, Christopher D., Kamel, Hooman, Woo, Daniel, Sheth, Kevin N., and Rosand, Jonathan
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2020
- Full Text
- View/download PDF
33. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials
- Author
-
Cudkowicz, Merit, Chase, Marianne K., Coffey, Christopher S., Ecklund, Dixie J., Thornell, Brenda J., Lungu, Codrin, Mahoney, Katy, Gutmann, Laurie, Shefner, Jeremy M., Staley, Kevin J., Bosch, Michael, Foster, Eric, Long, Jeffrey D., Bayman, Emine O., Torner, James, Yankey, Jon, Peters, Richard, Huff, Trevis, Conwit, Robin A., Shinnar, Shlomo, Patch, Donna, Darras, Basil T., Ellis, Audrey, Packer, Roger J., Marder, Karen S., Chiriboga, Claudia A., Henchcliffe, Claire, Moran, Joyce Ann, Nikolov, Blagovest, Factor, Stewart A., Seeley, Carole, Greenberg, Steven M., Amato, Anthony A., DeGregorio, Sara, Simuni, Tanya, Ward, Tina, Kissel, John T., Kolb, Stephen J., Bartlett, Amy, Quinn, Joseph F., Keith, Kellie, Levine, Steven R., Gilles, Nadege, Coyle, Patricia K., Lamb, Jessica, Wolfe, Gil I., Crumlish, Annemarie, Mejico, Luis, Iqbal, Muhammad Maaz, Bowen, James D., Tongco, Caryl, Nabors, Louis B., Bashir, Khurram, Benge, Melanie, McDonald, Craig M., Henricson, Erik K., Oskarsson, Björn, Dobkin, Bruce H., Canamar, Catherine, Glauser, Tracy A., Woo, Daniel, Molloy, Angela, Clark, Peggy, Vollmer, Timothy L., Stein, Alexander J., Barohn, Richard J., Dimachkie, Mazen M., Le Pichon, Jean-Baptiste, Benatar, Michael G., Steele, Julie, Wechsler, Lawrence, Clemens, Paula R., Amity, Christine, Holloway, Robert G., Annis, Christine, Goldberg, Mark P., Andersen, Mariam, Iannaccone, Susan T., Smith, A. Gordon, Singleton, J. Robinson, Doudova, Mariana, Haley, E. Clarke, Quigg, Mark S., Lowenhaupt, Stephanie, Malow, Beth A., Adkins, Karen, Clifford, David B., Teshome, Mengesha A., and Connolly, Noreen
- Abstract
IMPORTANCE: One major advantage of developing large, federally funded networks for clinical research in neurology is the ability to have a trial-ready network that can efficiently conduct scientifically rigorous projects to improve the health of people with neurologic disorders. OBSERVATIONS: National Institute of Neurological Disorders and Stroke Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) was established in 2011 and renewed in 2018 with the goal of being an efficient network to test between 5 and 7 promising new agents in phase II clinical trials. A clinical coordinating center, data coordinating center, and 25 sites were competitively chosen. Common infrastructure was developed to accelerate timelines for clinical trials, including central institutional review board (a first for the National Institute of Neurological Disorders and Stroke), master clinical trial agreements, the use of common data elements, and experienced research sites and coordination centers. During the first 7 years, the network exceeded the goal of conducting 5 to 7 studies, with 9 funded. High interest was evident by receipt of 148 initial applications for potential studies in various neurologic disorders. Across the first 8 studies (the ninth study was funded at end of initial funding period), the central institutional review board approved the initial protocol in a mean (SD) of 59 (21) days, and additional sites were added a mean (SD) of 22 (18) days after submission. The median time from central institutional review board approval to first site activation was 47.5 days (mean, 102.1; range, 1-282) and from first site activation to first participant consent was 27 days (mean, 37.5; range, 0-96). The median time for database readiness was 3.5 months (mean, 4.0; range, 0-8) from funding receipt. In the 4 completed studies, enrollment met or exceeded expectations with 96% overall data accuracy across all sites. Nine peer-reviewed manuscripts were published, and 22 oral presentations or posters and 9 invited presentations were given at regional, national, and international meetings. CONCLUSIONS AND RELEVANCE: NeuroNEXT initiated 8 studies, successfully enrolled participants at or ahead of schedule, collected high-quality data, published primary results in high-impact journals, and provided mentorship, expert statistical, and trial management support to several new investigators. Partnerships were successfully created between government, academia, industry, foundations, and patient advocacy groups. Clinical trial consortia can efficiently and successfully address a range of important neurologic research and therapeutic questions.
- Published
- 2020
- Full Text
- View/download PDF
34. Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity: A Meta-analysis
- Author
-
Marini, Sandro, Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Pezzini, Alessandro, Moomaw, Charles J., Flaherty, Matthew L., Montaner, Joan, Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Elosua, Roberto, Cuadrado-Godia, Elisa, Soriano-Tarraga, Carolina, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., McCauley, Jacob L., Tirschwell, David L., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Testai, Fernando D., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Rannikmae, Kristiina, Samarasekera, Neshika, Salman, Rustam Al-Shahi, Sudlow, Catherine L., Klijn, Catharina J. M., van Nieuwenhuizen, Koen M., Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, and Anderson, Christopher D.
- Abstract
IMPORTANCE: Genetic studies of intracerebral hemorrhage (ICH) have focused mainly on white participants, but genetic risk may vary or could be concealed by differing nongenetic coexposures in nonwhite populations. Transethnic analysis of risk may clarify the role of genetics in ICH risk across populations. OBJECTIVE: To evaluate associations between established differences in ICH risk by race/ethnicity and the variability in the risks of apolipoprotein E (APOE) ε4 alleles, the most potent genetic risk factor for ICH. DESIGN, SETTING, AND PARTICIPANTS: This case-control study of primary ICH meta-analyzed the association of APOE allele status on ICH risk, applying a 2-stage clustering approach based on race/ethnicity and stratified by a contributing study. A propensity score analysis was used to model the association of APOE with the burden of hypertension across race/ethnic groups. Primary ICH cases and controls were collected from 3 hospital- and population-based studies in the United States and 8 in European sites in the International Stroke Genetic Consortium. Participants were enrolled from January 1, 1999, to December 31, 2017. Participants with secondary causes of ICH were excluded from enrollment. Controls were regionally matched within each participating study. MAIN OUTCOMES AND MEASURES: Clinical variables were systematically obtained from structured interviews within each site. APOE genotype was centrally determined for all studies. RESULTS: In total, 13 124 participants (7153 [54.5%] male with a median [interquartile range] age of 66 [56-76] years) were included. In white participants, APOE ε2 (odds ratio [OR], 1.49; 95% CI, 1.24-1.80; P < .001) and APOE ε4 (OR, 1.51; 95% CI, 1.23-1.85; P < .001) were associated with lobar ICH risk; however, within self-identified Hispanic and black participants, no associations were found. After propensity score matching for hypertension burden, APOE ε4 was associated with lobar ICH risk among Hispanic (OR, 1.14; 95% CI, 1.03-1.28; P = .01) but not in black (OR, 1.02; 95% CI, 0.98-1.07; P = .25) participants. APOE ε2 and ε4 did not show an association with nonlobar ICH risk in any race/ethnicity. CONCLUSIONS AND RELEVANCE: APOE ε4 and ε2 alleles appear to affect lobar ICH risk variably by race/ethnicity, associations that are confirmed in white individuals but can be shown in Hispanic individuals only when the excess burden of hypertension is propensity score–matched; further studies are needed to explore the interactions between APOE alleles and environmental exposures that vary by race/ethnicity in representative populations at risk for ICH.
- Published
- 2019
- Full Text
- View/download PDF
35. Vascular contributions to cognitive impairment and dementia: Research consortia that focus on etiology and treatable targets to lessen the burden of dementia worldwide
- Author
-
Gladman, Jordan T., Corriveau, Roderick A., Debette, Stephanie, Dichgans, Martin, Greenberg, Steven M., Sachdev, Perminder S., Wardlaw, Joanna M., and Biessels, Geert Jan
- Abstract
The research into vascular contributions to cognitive impairment and dementia (VCID) aims to understand the importance of cerebrovascular biology in cognitive decline. Prevention and treatment of VCID is poised to have major impact on dementia-related disease burden and is thus a critical emerging objective in dementia research. This article presents VCID consortia focused on multidisciplinary approaches to identify key pathologic targets and develop diagnostic tools with the goal of bridging the divide between basic research and clinical trials. Members of these multi-institute, multidisciplinary consortia provide a prospective on the history and emerging science of VCID and how VCID consortia can address some of the more complex questions in VCID and drive the field forward. These consortia, and others like them, are uniquely suited to tackle some of the most difficult obstacles in translating research to the clinic.
- Published
- 2019
- Full Text
- View/download PDF
36. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage
- Author
-
Murphy, Meredith P., Kuramatsu, Joji B., Leasure, Audrey, Falcone, Guido J., Kamel, Hooman, Sansing, Lauren H., Kourkoulis, Christina, Schwab, Kristin, Elm, Jordan J., Gurol, M. Edip, Tran, Huy, Greenberg, Steven M., Viswanathan, Anand, Anderson, Christopher D., Schwab, Stefan, Rosand, Jonathan, Shi, Fu-Dong, Kittner, Steven J., Testai, Fernando D., Woo, Daniel, Langefeld, Carl D., James, Michael L., Koch, Sebastian, Huttner, Hagen B., Biffi, Alessandro, and Sheth, Kevin N.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
37. PS-P08-4: FOXO3 LONGEVITY GENOTYPE ATTENUATES THE IMPACT OF HYPERTENSION ON RISK OF INTRACEREBRAL HEMORRHAGE
- Author
-
Nakagawa, Kazuma, Randi, Chen, Greenberg, Steven M, Ross, G Webster, Willcox, Bradley J, Donlon, Timothy A, Allsopp, Richard C, Willcox, D Craig, Masaki, Kamal H, and Morris, Brian J
- Published
- 2023
- Full Text
- View/download PDF
38. Integration of Computed Tomographic Angiography Spot Sign and Noncontrast Computed Tomographic Hypodensities to Predict Hematoma Expansion
- Author
-
Morotti, Andrea, Boulouis, Gregoire, Charidimou, Andreas, Schwab, Kristin, Kourkoulis, Christina, Anderson, Christopher D., Gurol, M. Edip, Viswanathan, Anand, Romero, Javier M., Greenberg, Steven M., Rosand, Jonathan, and Goldstein, Joshua N.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
39. Cerebral Amyloid Angiopathy With Vascular Iron Accumulation and Calcification
- Author
-
Bulk, Marjolein, Moursel, Laure Grand, van der Graaf, Linda M., van Veluw, Susanne J., Greenberg, Steven M., van Duinen, Sjoerd G., van Buchem, Mark A., van Rooden, Sanneke, and van der Weerd, Louise
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
40. Perivascular Spaces Volume in Sporadic and Hereditary (Dutch-Type) Cerebral Amyloid Angiopathy
- Author
-
Martinez-Ramirez, Sergi, van Rooden, Sanneke, Charidimou, Andreas, van Opstal, Anna Maria, Wermer, Marieke, Gurol, M. Edip, Terwindt, Gisela, van der Grond, Jeroen, Greenberg, Steven M., van Buchem, Mark, and Viswanathan, Anand
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
41. 17p12Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage
- Author
-
Marini, Sandro, Devan, William J., Radmanesh, Farid, Miyares, Laura, Poterba, Timothy, Hansen, Björn M., Norrving, Bo, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Elosua, Roberto, Cuadrado-Godia, Elisa, Soriano, Carolina, Roquer, Jaume, Kourkoulis, Christina E., Ayres, Alison M., Schwab, Kristin, Tirschwell, David L., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Montaner, Joan, Fernandez-Cadenas, Israel, Delgado, Pilar, Greenberg, Steven M., Lindgren, Arne, Matouk, Charles, Sheth, Kevin N., Woo, Daniel, Anderson, Christopher D., Rosand, Jonathan, and Falcone, Guido J.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
42. Cerebral Microbleeds and the Effect of Intensive Blood Pressure Reduction on Hematoma Expansion and Functional Outcomes: A Secondary Analysis of the ATACH-2 Randomized Clinical Trial
- Author
-
Shoamanesh, Ashkan, Morotti, Andrea, Romero, Javier M., Oliveira-Filho, Jamary, Schlunk, Frieder, Jessel, Michael J., Ayres, Alison M., Vashkevich, Anastasia, Schwab, Kristin, Afzal, Mohammad R., Cassarly, Christy, Martin, Renee H., Qureshi, Adnan I., Greenberg, Steven M., Rosand, Jonathan, and Goldstein, Joshua N.
- Abstract
IMPORTANCE: Response to intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH) might vary with the degree of underlying cerebral small vessel disease. OBJECTIVES: To characterize cerebral microbleeds (CMBs) in acute ICH and to assess the potential for interaction between underlying small vessel disease (as indicated by CMB number and location) and assignment to acute intensive BP targeting for functional outcomes and hematoma expansion. DESIGN, SETTING, AND PARTICIPANTS: Preplanned subgroup analyses in the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial were performed. The ATACH-2 was an open-label international randomized clinical trial that investigated optimal acute BP lowering in 1000 patients with acute ICH. Analyses followed the intent-to-treat paradigm. Participants were enrolled between May 2011 and September 2015 and followed up for 3 months. Eligible participants were aged at least 18 years with ICH volumes less than 60 mL on computed tomography (CT) and a Glasgow Coma Scale score of at least 5 on initial assessment, in whom study drug could be initiated within 4.5 hours of symptom onset. Eight hundred thirty-three participants were excluded, leaving 167 who had an interpretable axial T2*-weighted gradient-recalled echo sequence on magnetic resonance imaging to assess CMBs for inclusion in these subgroup analyses. MAIN OUTCOMES AND MEASURES: The primary outcome of interest was death or disability (modified Ranking Scale score, 4-6) at 3 months. The secondary outcome of interest was hematoma volume expansion of at least 33% on a CT scan obtained 24 hours after randomization compared with the entry scan. RESULTS: A total of 167 patients were included; their mean (SD) age was 61.9 (13.2) years, and 98 (58.7%) were male. Cerebral microbleeds were present in 120 patients. Forty-six of 157 (29.3%) patients had poor outcome (modified Ranking Scale score, ≥4), and hematoma expansion was observed in 29 of 144 (20.1%) patients. Risk of poor outcome was similar for those assigned to intensive vs standard acute BP lowering among patients with CMBs (relative risk, 1.19; 95% CI, 0.61-2.33; P = .61) and those without CMBs (relative risk, 1.42; 95% CI, 0.43-4.70; P = .57), and no significant interaction was observed (interaction coefficient, 0.18; 95% CI, −1.20 to 1.55; P = .80). Risk of hematoma expansion was also similar, and no significant interaction between treatment and CMBs was observed (interaction coefficient, 0.62; 95% CI, −1.08 to 2.31; P = .48). CONCLUSIONS AND RELEVANCE: Cerebral microbleeds are highly prevalent among patients with ICH but do not seem to influence response to acute intensive BP treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01176565
- Published
- 2018
- Full Text
- View/download PDF
43. Advances in Stroke 2017
- Author
-
Bernhardt, Julie, Zorowitz, Richard D., Becker, Kyra J., Keller, Emanuela, Saposnik, Gustavo, Strbian, Daniel, Dichgans, Martin, Woo, Daniel, Reeves, Mathew, Thrift, Amanda, Kidwell, Chelsea S., Olivot, Jean Marc, Goyal, Mayank, Pierot, Laurent, Bennett, Derrick A., Howard, George, Ford, Gary A., Goldstein, Larry B., Planas, Anna M., Yenari, Midori A., Greenberg, Steven M., Pantoni, Leonardo, Amin-Hanjani, Sepideh, and Tymianski, Michael
- Published
- 2018
- Full Text
- View/download PDF
44. Predicting Intracerebral Hemorrhage Expansion With Noncontrast Computed Tomography
- Author
-
Morotti, Andrea, Dowlatshahi, Dar, Boulouis, Gregoire, Al-Ajlan, Fahad, Demchuk, Andrew M., Aviv, Richard I., Yu, Liyang, Schwab, Kristin, Romero, Javier M., Gurol, M. Edip, Viswanathan, Anand, Anderson, Christopher D., Chang, Yuchiao, Greenberg, Steven M., Qureshi, Adnan I., Rosand, Jonathan, and Goldstein, Joshua N.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
45. The growing clinical spectrum of cerebral amyloid angiopathy
- Author
-
Wermer, Marieke J.H. and Greenberg, Steven M.
- Published
- 2018
- Full Text
- View/download PDF
46. Diagnosis of Cerebral Amyloid Angiopathy
- Author
-
Greenberg, Steven M. and Charidimou, Andreas
- Published
- 2018
- Full Text
- View/download PDF
47. Blood pressure from mid‐ to late life and risk of incident dementia
- Author
-
McGrath, Emer R., Beiser, Alexa S., DeCarli, Charles, Plourde, Kendra L., Vasan, Ramachandran S., Greenberg, Steven M., and Seshadri, Sudha
- Published
- 2017
- Full Text
- View/download PDF
48. Alzheimer's Disease–Related Dementias Summit 2016: National research priorities
- Author
-
Corriveau, Roderick A., Koroshetz, Walter J., Gladman, Jordan T., Jeon, Sophia, Babcock, Debra, Bennett, David A., Carmichael, S. Thomas, Dickinson, Susan L.-J., Dickson, Dennis W., Emr, Marian, Fillit, Howard, Greenberg, Steven M., Hutton, Michael L., Knopman, David S., Manly, Jennifer J., Marder, Karen S., Moy, Claudia S., Phelps, Creighton H., Scott, Paul A., Seeley, William W., Sieber, Beth-Anne, Silverberg, Nina B., Sutherland, Margaret L., Taylor, Angela, Torborg, Christine L., Waddy, Salina P., Gubitz, Amelie K., and Holtzman, David M.
- Abstract
Goal 1 of the National Plan to Address Alzheimer’s Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease–related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease–Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixed-etiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.
- Published
- 2017
- Full Text
- View/download PDF
49. Cortical superficial siderosis multifocality in cerebral amyloid angiopathy
- Author
-
Charidimou, Andreas, Boulouis, Gregoire, Roongpiboonsopit, Duangnapa, Auriel, Eitan, Pasi, Marco, Haley, Kellen, van Etten, Ellis S., Martinez-Ramirez, Sergi, Ayres, Alison, Vashkevich, Anastasia, Schwab, Kristin M., Goldstein, Joshua N., Rosand, Jonathan, Viswanathan, Anand, Greenberg, Steven M., and Gurol, M. Edip
- Published
- 2017
- Full Text
- View/download PDF
50. Evolution of DWI lesions in cerebral amyloid angiopathy
- Author
-
van Veluw, Susanne J., Lauer, Arne, Charidimou, Andreas, Bounemia, Narimene, Xiong, Li, Boulouis, Gregoire, Fotiadis, Panagiotis, Ayres, Alison, Gurol, M. Edip, Viswanathan, Anand, Greenberg, Steven M., and Vernooij, Meike W.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.